0000000001264601

AUTHOR

Christiane Windemuth-kieselbach

showing 1 related works from this author

Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-contr…

2014

1072 Background: Anti-angiogenic therapy with the monoclonal anti-VEGF antibody Bevacizumab (Bev) in combination with chemotherapy increases overall response rates (ORR) and progression free surviv...

OncologySorafenibCancer Researchmedicine.medical_specialtyChemotherapyBevacizumabbusiness.industrymedicine.medical_treatmentPharmacologyPlacebomedicine.diseaseMetastatic breast cancerOncologyDocetaxelInternal medicineMonoclonalMedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct